-
1
-
-
0033530262
-
Chemotherapy-induced anemia in adults: Incidence and treatment
-
Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-34
-
(1999)
J Natl Cancer Inst
, vol.91
, pp. 1616-1634
-
-
Groopman, J.E.1
Itri, L.M.2
-
2
-
-
21744439534
-
The anaemia of cancer: Death by a thousand cuts
-
Spivak JL. The anaemia of cancer: death by a thousand cuts. Nat Rev Cancer 2005;5:543-55
-
(2005)
Nat Rev Cancer
, vol.5
, pp. 543-555
-
-
Spivak, J.L.1
-
3
-
-
0035367087
-
Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial
-
Littlewood TJ, Bajetta E, Nortier JWR, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-74
-
(2001)
J Clin Oncol
, vol.19
, pp. 2865-2874
-
-
Littlewood, T.J.1
Bajetta, E.2
Nortier, J.W.R.3
-
4
-
-
4344627592
-
Treatment of cancer-related anemia with epoetin alfa: A review
-
Ferrario E, Ferrari L, Bidoli P, et al. Treatment of cancer-related anemia with epoetin alfa: a review. Cancer Treat Rev 2004;30:563-75
-
(2004)
Cancer Treat Rev
, vol.30
, pp. 563-575
-
-
Ferrario, E.1
Ferrari, L.2
Bidoli, P.3
-
5
-
-
0031785039
-
Impact of epoetin alfa in chemotherapy-associated anemia
-
Jilani SM, Glapsy JA. Impact of epoetin alfa in chemotherapy-associated anemia. Semin Oncol 1998;25:571-6
-
(1998)
Semin Oncol
, vol.25
, pp. 571-576
-
-
Jilani, S.M.1
Glapsy, J.A.2
-
6
-
-
0036787775
-
Use of epoetin alfa in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology
-
Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin alfa in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-107
-
(2002)
J Clin Oncol
, vol.20
, pp. 4083-4107
-
-
Rizzo, J.D.1
Lichtin, A.E.2
Woolf, S.H.3
-
7
-
-
0035366382
-
Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing
-
Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-82
-
(2001)
J Clin Oncol
, vol.19
, pp. 2875-2882
-
-
Gabrilove, J.L.1
Cleeland, C.S.2
Livingston, R.B.3
-
8
-
-
26444555509
-
Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 μg every 2 weeks) in anemic patients with cancer receiving chemotherapy
-
Waltzman R, Croot C, Justice GR, et al. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 μg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 2005;10:642-50
-
(2005)
Oncologist
, vol.10
, pp. 642-650
-
-
Waltzman, R.1
Croot, C.2
Justice, G.R.3
-
9
-
-
21044442522
-
Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy
-
Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606-17
-
(2005)
J Clin Oncol
, vol.23
, pp. 2606-2617
-
-
Witzig, T.E.1
Silberstein, P.T.2
Loprinzi, C.L.3
-
10
-
-
1642498304
-
Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy
-
Patton J, Kuzur M, Liggett W, et al. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy. Oncologist 2004;9:90-6
-
(2004)
Oncologist
, vol.9
, pp. 90-96
-
-
Patton, J.1
Kuzur, M.2
Liggett, W.3
-
11
-
-
33644977733
-
Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer
-
Steensma DP, Molina R, Sloan JA, et al. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol 2006;24:1079-89
-
(2006)
J Clin Oncol
, vol.24
, pp. 1079-1089
-
-
Steensma, D.P.1
Molina, R.2
Sloan, J.A.3
-
12
-
-
26444599396
-
-
Raritan, NJ: Ortho Biotech Products, L.P.
-
PROCRIT® Package Insert. Raritan, NJ: Ortho Biotech Products, L.P.; 2005
-
(2005)
PROCRIT® Package Insert
-
-
-
13
-
-
0042889128
-
Once-weekly dosing of epoetin-α increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy
-
Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin-α increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003;98:1072-9
-
(2003)
Cancer
, vol.98
, pp. 1072-1079
-
-
Shasha, D.1
George, M.J.2
Harrison, L.B.3
-
14
-
-
25444497001
-
Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents
-
Mark TL, McKenzie RS, Fastenau J, Piech CT. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents. Curr Med Res Opin 2005;21:1347-54
-
(2005)
Curr Med Res Opin
, vol.21
, pp. 1347-1354
-
-
Mark, T.L.1
McKenzie, R.S.2
Fastenau, J.3
Piech, C.T.4
-
15
-
-
17044394034
-
Evolving treatment approaches to early breast cancer
-
Campon SM. Evolving treatment approaches to early breast cancer. Breast Cancer Res Treat 2005;89(Suppl 1):S1-7
-
(2005)
Breast Cancer Res Treat
, vol.89
, Issue.SUPPL. 1
-
-
Campon, S.M.1
-
16
-
-
0036957334
-
Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma: A phase II study
-
Viret F, Bertucci F, Genre D, et al. Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma: a phase II study. Bone Marrow Transplant 2002;30:879-84
-
(2002)
Bone Marrow Transplant
, vol.30
, pp. 879-884
-
-
Viret, F.1
Bertucci, F.2
Genre, D.3
-
17
-
-
14644406208
-
Evaluation of anemia, neutropenia, and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer
-
Schwartz J, Domcheck SM, Hwang WT, Fox K. Evaluation of anemia, neutropenia, and skin toxicities in standard or dose-dense doxorubicin/ cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer. Ann Oncol 2005;16:247-52
-
(2005)
Ann Oncol
, vol.16
, pp. 247-252
-
-
Schwartz, J.1
Domcheck, S.M.2
Hwang, W.T.3
Fox, K.4
-
18
-
-
28844440074
-
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every 2 week adjuvant breast cancer chemotherapy
-
Burstein HJ, Parker LM, Keshaviah A, et al. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every 2 week adjuvant breast cancer chemotherapy. J Clin Oncol 2005;23:8340-7
-
(2005)
J Clin Oncol
, vol.23
, pp. 8340-8347
-
-
Burstein, H.J.1
Parker, L.M.2
Keshaviah, A.3
-
19
-
-
33644818721
-
Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia
-
Campos SM, Duh MS, Lefebvre P, Rosberg J. Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia. J Natl Compr Cane Netw 2005;3:807-16
-
(2005)
J Natl Compr Cane Netw
, vol.3
, pp. 807-816
-
-
Campos, S.M.1
Duh, M.S.2
Lefebvre, P.3
Rosberg, J.4
-
20
-
-
27144435165
-
Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia
-
Reed SD, Radheva JI, Daniel DB et al. Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia. Curr Med Res Opin 2005;21:1527-33
-
(2005)
Curr Med Res Opin
, vol.21
, pp. 1527-1533
-
-
Reed, S.D.1
Radheva, J.I.2
Daniel, D.B.3
|